Search results
Results from the WOW.Com Content Network
Intellia prioritized NTLA-2002 and nex-z while discontinuing the NTLA-3001 program and other early-stage initiatives. ... January 10, 2025 at 12:30 PM. ... Price Action: NTLA stock is down 12.7% ...
Based on these factors, Intellia Therapeutics won't get a boost to its stock price anywhere close to what Wall Street predicts in the next 12 months. That alone doesn't mean the stock isn't a buy ...
In this article you are going to find out whether hedge funds think Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a good investment right now. We like to check what the smart money thinks first ...
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. [3] NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. [4]
Given his 6,100 call for the end of 2024, Belski's forecast returns in 2025 at 9.8%, right in line with the index's average historical gain. The median year-end target for the S&P 500 among ...
The only stock to drag more on the market was Eli Lilly, which fell 6.6% after saying it expects to report weaker revenue for the last three months of 2024 than previously forecast.
Listen and subscribe to Stocks in Translation on Apple Podcasts, Spotify, or wherever you find your favorite podcasts.. 2024 was a year of financial surprises for many investors. The S&P 500 index ...
The stock market has stumbled in recent weeks as rates have soared. This action played out on Friday as the 10-year Treasury yield ( ^TNX ) added about five basis points to creep near 4.8%, its ...